Showing 961-970 of 1043 results for "".
- Investigational MS Treatment Diroximel Fumarate Has Improved Gastrointestinal Tolerabilityhttps://practicalneurology.com/news/investigational-ms-treatment-diroximel-fumarate-has-improved-gastrointestinal-tolerability/2468982/Topline results from the EVOLVE-MS-2 study (NCT02634307), of diroximel fumarate (ALKS8700, BIIB098; Alkermes, Waltham, MA and Biogen, Cambridge, MA) for treatment of relapsing-remitting multiple sclerosis (RRMS) have been announced. Pa
- NCCN Guidelines for Treatment of H3 K27M-Mutant Diffuse Glioma Updatedhttps://practicalneurology.com/news/nccn-guidelines-for-treatment-of-h3-k27m-mutant-diffuse-glioma-updated/2483322/The National Comprehensive Cancer Network (NCCN; Plymouth Meeting, PA) has included Modeyso (dordaviprone; Jazz Pharmaceuticals, Dublin, Ireland) in its Clinical Practice Guidelines in Oncology as a category 2A recommended treatment option for adults and children with recurrent or progressive dif
- Labcorp Launches FDA-Cleared Blood Test for Alzheimer’shttps://practicalneurology.com/news/labcorp-launches-fda-cleared-blood-test-for-alzheimers/2483033/Labcorp (Burlington, NC) has announced the launch of Lumipulse G pTau 217/ β-Amyloid 1-42 Plasma Ratio (Fujirebio Diagnostics, Malvern, PA), which is the first Food and Drug Administration (FDA)–cleared blood-based test that can be used to aid in the diagnostic evaluation ofAlzheimer disease (AD)
- Quest Diagnostics to Launch FDA-Cleared Blood Test for Alzheimer Disease Assessmenthttps://practicalneurology.com/news/quest-diagnostics-to-launch-fda-cleared-blood-test-for-alzheimer-disease-assessment/2475681/Quest Diagnostics (Secaucus, NJ) announced plans to begin offering the Lumipulse G pTau 217/β-Amyloid 1-42 diagnostic test (Fujirebio Diagnostics, Malvern, PA) later in the summer of 2025 to physicians and biopharmaceutical collaborators. The Lumipulse test is the first Food and Drug Administrati
- Wakix Shows Potential as Treatment for Individuals with Idiopathic Hypersomniahttps://practicalneurology.com/news/wakix-shows-potential-as-treatment-for-individuals-with-idiopathic-hyerpsomnia/2475071/A comprehensive analysis of 2 phase 3 clinical trials demonstrated that Wakix (pitolisant; Harmony Biosciences, Plymouth Meeting, PA) maintained a favorable safety profile and provided clinically meaningful improvements for multiple symptoms in adults diagnosed with idiopathic hypersomnia (IH). T
- Plasma Biomarker Test to Aid in Alzheimer’s Diagnosis Cleared by FDAhttps://practicalneurology.com/news/plasma-biomarker-test-to-aid-in-alzheimers-diagnosis-cleared-by-fda/2474763/The Food and Drug Administration (FDA) has announced the 410(k) clearance of the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio (Fujirebio Diagnostics, Malvern, PA) to aid in the diagnostic evaluation of Alzheimer disease (AD), marking it the first in vitro diagnostic test for this disease state
- Non-Opioid Drug Significantly Reduced Pain After Surgery, Studies Revealhttps://practicalneurology.com/news/non-opioid-drug-significantly-reduced-pain-after-surgery-studies-reveal/2474650/Treatment with MR-107A-02 (meloxicam; Viatris, Pittsburgh, PA), a novel, oral, fast-acting formulation of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, was shown to significantly reduce pain and opioid usage vs placebo in top-line results from 2 phase 3 clinical studies. Additionally
- New Insights into Diagnosis, Treatment, and Disability in People Living with Guillain-Barre Syndromehttps://practicalneurology.com/news/new-insights-into-diagnosis-treatment-and-disability-in-people-living-with-guillain-barre-syndrome/2473807/Most people with Guillain-Barré syndrome (GBS) have difficulty using stairs, completing chores, and participating in leisure activities with family and friends, according to a new patient registry report published by GBS|CIDP Foundation International (Conshohocken, PA). The results of a su
- Intracranial Pressure–Monitoring Device Receives Breakthrough Device Designation for Hydrocephalushttps://practicalneurology.com/news/intracranial-pressure-monitoring-device-receives-breakthrough-device-designation-for-hydrocephalus/2470567/The Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the M.scio System (Aesculap, Center Valley, PA; Miethke, Potsdam, Germany), expediting the device’s development for managing and improving care for individuals with hydrocephalus. The M.scio System consis
- Discrepancies Discovered in the Treatment of People with Refractory Epilepsy by Epileptologists vs General Neurologistshttps://practicalneurology.com/news/discrepancies-discovered-in-the-treatment-of-people-with-refractory-epilepsy-by-epileptologists-vs-general-neurologists/2470523/Epileptologists and general neurologists have different approaches to treating people with refractory epilepsy, according to the Market Dynamix: Adult Refractory Epilepsy (US) study conducted by Spherix Global Insights (Exton, PA). Researchers found that general neurologists treat approximately 2